Cargando…

Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants

CD47 transduces inhibitory signals through signal-regulatory protein α (SIRPα), a plasma membrane receptor expressed by macrophages. Many cancers upregulate CD47 to evade immunosurveillance. We have recently engineered SIRPα variants that potently antagonize CD47 for use as anticancer immunotherapeu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weiskopf, Kipp, Ring, Aaron M, Schnorr, Peter J, Volkmer, Jens-Peter, Volkmer, Anne Kathrin, Weissman, Irving L, Garcia, K Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850276/ https://www.ncbi.nlm.nih.gov/pubmed/24319639 http://dx.doi.org/10.4161/onci.25773

Ejemplares similares

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
por: Edris, Badreddin, et al.
Publicado: (2013)

Flipping the script on macrophages in leiomyosarcoma
por: Edris, Badreddin, et al.
Publicado: (2012)

Targeting SIRPα in cancer
por: Ho, Jenny M., et al.
Publicado: (2013)

Macrophages are critical effectors of antibody therapies for cancer
por: Weiskopf, Kipp, et al.
Publicado: (2015)

CD47-blocking therapies stimulate macrophage cytokine secretion and are effective in a model of peritoneal carcinomatosis
por: Weiskopf, Kipp, et al.
Publicado: (2015)

Engineered tumor-infiltrating macrophages as gene delivery vehicles for interferon-α activates immunity and inhibits breast cancer progression
por: Escobar, Giulia, et al.
Publicado: (2014)

Anticancer efficacy of monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages
por: Sakamoto, Mariko, et al.
Publicado: (2021)

Macrophages in the liver prevent metastasis by efficiently eliminating circulating tumor cells after monoclonal antibody immunotherapy
por: Gül, Nuray, et al.
Publicado: (2014)

Remote control of macrophage production by cancer
por: Cortez-Retamozo, Virna, et al.
Publicado: (2013)

Macrophages: Good guys in colorectal cancer
por: Edin, Sofia, et al.
Publicado: (2013)

Function-first antibody discovery: Embracing the unpredictable biology of antibodies
por: Frendéus, Björn
Publicado: (2013)

CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies
por: Andrechak, Jason C., et al.
Publicado: (2022)

Cancer-associated fibroblasts and macrophages: Friendly conspirators for malignancy
por: Chiarugi, Paola
Publicado: (2013)

Modifying tumor-associated macrophages: An important adjunct to immunotherapy
por: Fridlender, Zvi G, et al.
Publicado: (2013)

Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2013)

Altering the intratumoral localization of macrophages to inhibit cancer progression
por: Casazza, Andrea, et al.
Publicado: (2014)

Molecular regulation of macrophages in unleashing cancer-related inflammation
por: Hong, Feng, et al.
Publicado: (2014)

Engineering effective T-cell based antitumor immunity
por: Gruber, Thomas, et al.
Publicado: (2013)

Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis
por: Lizotte, Patrick H, et al.
Publicado: (2014)

TAMable tumor-associated macrophages in response to innate RNA sensing
por: Seya, Tsukasa, et al.
Publicado: (2012)

Application of iPS cell-derived macrophages to cancer therapy
por: Senju, Satoru, et al.
Publicado: (2014)

TAM macrophages promote growth and metastasis within the cancer ecosystem
por: Zarif, Jelani C, et al.
Publicado: (2014)

Role of c-MYC in tumor-associated macrophages and cancer progression
por: Pello, Oscar M., et al.
Publicado: (2013)

Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
por: Abate-Daga, Daniel, et al.
Publicado: (2014)

Interferon α interferes with immunological tolerance
por: Becker, Christian, et al.
Publicado: (2013)

Intratumoral TNFα improves immunotherapy
por: Johansson, Anna, et al.
Publicado: (2012)

Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
por: Houot, Roch, et al.
Publicado: (2012)

Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages
por: Cavnar, Michael J, et al.
Publicado: (2014)

The battle for the brain: Brain tumor-initiating cells vs. microglia/macrophages
por: Sarkar, Susobhan, et al.
Publicado: (2014)

Trabectedin: A drug from the sea that strikes tumor-associated macrophages
por: Allavena, Paola, et al.
Publicado: (2013)

Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists
por: Luheshi, Nadia, et al.
Publicado: (2014)

Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2021)

CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022)

Engineering hematopoietic stem cells to create melanoma specific CTL
por: Vatakis, Dimitrios
Publicado: (2012)

Engineering Grp170-based immune modulators for cancer immunotherapy
por: Yu, Xiaofei, et al.
Publicado: (2013)

Hypoxia and tumor-associated macrophages: A deadly alliance in support of tumor progression
por: Van Overmeire, Eva, et al.
Publicado: (2014)

Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase
por: Amit, Moran, et al.
Publicado: (2013)

The macrophage: Switches from a passenger to a driver during anticancer therapy
por: Wang, Tao, et al.
Publicado: (2015)

Breaking the vicious cycle between breast cancer cells and tumor-associated macrophages
por: Su, Shicheng, et al.
Publicado: (2014)

Approaching untargetable tumor-associated antigens with antibodies
por: Dao, Tao, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_emmebg5blh5cbc5snh1mbh5ckh